# Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome.

> **NCT00401830** · PHASE2 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 159 (actual)

## Conditions studied

- Fibromyalgia Syndrome

## Interventions

- **DRUG:** Lacosamide
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00401830
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2018-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00401830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00401830, "Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00401830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*